Intellia Therapeutics price target raised to $14 from $12 at Citi

Citi analyst David Lebowitz raised the firm’s price target on Intellia Therapeutics (NTLA) to $14 from $12 and keeps a Neutral rating on the shares after the company reported FY24 results and reiterated plans for a year focused on clinical stage execution. Investors are looking forward to longer-term data from the nex-z Phase 1 study, which will be presented later this year providing insight into the sustainability of efficacy over a longer period, the analyst tells investors in a research note. The firm added that, following the report, it updated its model for Q4 actuals and adjusted its operating expense estimates.